TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Modified Yale Preoperative Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bell-Lysaker Emotion Recognition Task Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Facial Emotion Identification Test Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ambiguous Intentions and Hostility Scale - Hostility and Aggression Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Awareness of Social Inference Test Total Score for Part 3
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CT index - RA960
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT index - LA3rd
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT index - LA4th
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT index - WT3rd
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT index - WT4th
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle satellite cells number and activation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle myogenic mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in skeletal muscle damage levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients Completing Full 6 Cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who had one or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Annual Relapse Rate (ARR)
Endpoint domain: Mortality/survival
Primary endpoint: Microparticles level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Insulin Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: t½term
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Regimen-limiting Toxicities (RLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Carotid Plaque Neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Osteoarthritis Structural Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Evaluable Patients With Dose Limiting Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) by Measurement of Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of urinary NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Faces Pain Scale-Revised (FSP-R) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shannon Index (Alpha-Diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: borderline high blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxicity of proposed treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: post-op IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-op IOP clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drug resistance in AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of Vitamin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Memory for truth of information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total amount of benzodiazepines administrated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of influenza like illness
Endpoint domain: Adverse events/effects
Primary endpoint: Change in adherence to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in patient experience about his/her care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of foods in gram per day from different food groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calorie gap from different food groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Water Filled at Sensation Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of revisions and removals
Endpoint domain: Adverse events/effects
Primary endpoint: time to T4-dermatome sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in 6-minute hall walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of death (all-cause)
Endpoint domain: Mortality/survival
Primary endpoint: improvement in GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spoken language comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spoken language production (young children)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spoken language production (older children)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sound localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip hematoma size in USG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of rescue intubation and mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Pain during diagnostic hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Serum Trough Concentration (Ctrough) of Trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social anxiety symptom reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 14 day cause specific mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean pulmonary artery pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in central venous pressure (CVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma levels of sPRR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T2DM parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline of antidiuretic function parameters (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline of antidiuretic function parameters (vasopressin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from baseline of antidiuretic function parameters (osmolality)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline of antidiuretic function parameters (sodium balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline of antidiuretic function parameters (potassium balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of IMGN901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in McGill Pain Questionnaire, Short Form, Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of total weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of Arginine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of ADMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of SDMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of Citrulline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of DMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(0-T) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(INF) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in modified AIMS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Subjects With Treatment Emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Treatment Emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Pain measurement during labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Time to treatment related toxicity greater than grade 3
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: concentration of AZD8566 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of OZURDEX® Implant Reinjections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to OZURDEX® Reinjection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratio for having depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin thickening evaluated by Skin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation restriction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients Selected for Preferred Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum observed oxycodone concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the oxycodone concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with therapeutic trough concentration of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seroprotected for Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy against culture-confirmed influenza illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 36 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 60 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 120 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Characteristic Curve (AUROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: BOLD-level activity during the learning phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD-level activity during the learning transfer phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit of CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners' Abbreviated Parent Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood chemistry and hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse events including infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of blood products received
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of apical periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Weightloss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraventricular hemorrhage (IVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Periventricular leukomalacia (PVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinopathy of prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distance travelled during 6-minute walking distance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean crestal bone level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster University (WOMAC) osteoarthritis index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mortality and morbidity reduction
Endpoint domain: Mortality/survival
Primary endpoint: Change in swing phase gait components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee control during stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KID SSQ12 questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: humoral antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Swallowing Difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of NTM pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression-Free Rate at 4 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glucose and C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline of biomechanical measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of keratoconus progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of corneal-shape irregularities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in MSFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: intraoperatively administered fluid amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of covered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' knowledge regarding Trans Obturator Tape surgery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychosocial Stress: Insecurity (Regional Measure)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychosocial stress: Distress (Regional Measure)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychosocial Stress (International Measure)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alcohol consumption days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise or normalization of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin A1C (HbA1C) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early Neonatal Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: change in quantitative ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: timepoint of maximal ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-T), area under the concentration-time curve from time zero to the time of the last quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(INF), area under the concentration-time curve from time zero extrapolated to infinite time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Primary Safety Event
Endpoint domain: Adverse events/effects
Primary endpoint: Activity Retention Over Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Six-minute walk test (6-MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained normalisation of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of resolution of VUR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude and frequency of changes in free-run smooth muscle EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of RLS Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Scores (RLS-QLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average minutes of physical activity per day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quality of life of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Self-reported Overall Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Self-reported Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of international travel
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decreased frequency of HIV related behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of patients with at least one episode of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: mortality of exacerbated patients
Endpoint domain: Mortality/survival
Primary endpoint: Improved times for the obtainment of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) AUC (0-3 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive percent agreement for accurately detecting RTLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative percent agreement for accurately detecting the absence of RTLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes